These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37003543)

  • 1. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
    Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
    Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
    Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
    Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children.
    Luo J; Luo M; Kaminga AC; Wei J; Dai W; Peng Y; Zhao K; Duan Y; Xiao X; Ouyang S; Yao Z; Liu Y; Pan X
    Microbiol Spectr; 2024 Apr; 12(4):e0523022. PubMed ID: 38445874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
    Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
    Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity.
    Bertran L; Capellades J; Abelló S; Durán-Bertran J; Aguilar C; Martinez S; Sabench F; Correig X; Yanes O; Auguet T; Richart C
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37372937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma metabolomic profile in nonalcoholic fatty liver disease.
    Kalhan SC; Guo L; Edmison J; Dasarathy S; McCullough AJ; Hanson RW; Milburn M
    Metabolism; 2011 Mar; 60(3):404-13. PubMed ID: 20423748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential link between plasma short-chain fatty acids, TNF-α level and disease progression in non-alcoholic fatty liver disease: A retrospective study.
    Xiong J; Chen X; Zhao Z; Liao Y; Zhou T; Xiang Q
    Exp Ther Med; 2022 Sep; 24(3):598. PubMed ID: 35949337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
    Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
    Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease.
    Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY
    World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease.
    Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Han SH; Yang YJ; Baik GH; Bang CS; Kim DJ; Suk KT
    Hepatol Int; 2024 Apr; 18(2):486-499. PubMed ID: 37000389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach.
    Ioannou GN; Nagana Gowda GA; Djukovic D; Raftery D
    Metabolites; 2020 Apr; 10(4):. PubMed ID: 32344559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of (20 R)-Panaxadiol on NAFLD using non‑targeted metabolomics in stool.
    Feng J; Cheng F; Lv Y; Yu Z; Zhang M; Chen L; Xu M; Guan F
    J Pharm Biomed Anal; 2023 Sep; 234():115555. PubMed ID: 37473506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry.
    Hu C; Wang T; Zhuang X; Sun Q; Wang X; Lin H; Feng M; Zhang J; Cao Q; Jiang Y
    J Transl Med; 2021 Apr; 19(1):152. PubMed ID: 33858428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.